GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards for the period ended 31st March, 2021.
Glenmark Pharma gets USFDA approval for generic lung cancer drug
Glenmark Pharmaceuticals said it has received approval from the US health regulator to market Nintedanib capsules, used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg
Glenmark Pharma gets USFDA nod for inhalation product
The approved product is a generic version of Brovana Inhalation Solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark launches Tiogiva(r), becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler
Glenmark Pharma releases interim data from PMS study on Favipiravir
Glenmark Pharmaceuticals announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark's interim data from PMS Study on Favipiravir (FabiFlu(r)) supports its safety and effectiveness in real world settings with no new safety signals or concerns in Covid-19 patients
Buy Glenmark Pharmaceuticals; target of Rs 717: Geojit
Geojit is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 717 in its research report dated June 03, 2021.Glenmark Pharma gets final nod from USFDA for Theophylline ER tablets
Eligible for 180 days of competitive generic therapy exclusivity for commercial marketing of 450 mg strength